investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
Pharmacogenetics of Phase II Drug Metabolizing Enzymes
Richard M Weinshilboum
2 Collaborator(s)
Funding source
National Institute of General Medical Sciences (NIH)
Follow
+ Project
+ Post
+ Event
Info
People
Posts
No posts
Related projects
Kornelia Polyak
Targeting intratumor heterogeneity in breast cancer
Breast
Fabio Petrocca
Noxa-mediated mechanisms of proteasome addiction in basal-like breast cancer
Breast
Susan L Teitelbaum
Breast Cancer Genomics in Windows of Susceptibility to Endocrine Disruptors
Breast
Jie Liu
Structure and Function of the Tumor Suppressor Protein BRCA2
Breast
Michael Bustin
Biological Functions of Chromosomal Proteins
Breast
Radiation Oncology
Pediatric oncology or childhood cancer
Bert W O'Malley
Reproductive Hormones - Biological and Molecular Actions
Breast
Needs Assessment to Assess Barriers to Developing a Comprehensive Cancer Center in LMICs
Breast
Philip Tofilon
Radiation-induced translational control of gene expression
Breast
Radiation Oncology
Fraser Symmans
Development of A Predictive Genomic Diagnostic Test for Survival Benefit from Everolimus (mTOR Inhibitor) Combined with Endocrine Therapy for Metastatic HR+/HER- Breast Cancer
Breast